Literature DB >> 14715764

Effects of inoculum and beta-lactamase activity in AmpC- and extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae clinical isolates tested by using NCCLS ESBL methodology.

Anne Marie Queenan1, Barbara Foleno, Colleen Gownley, Ellyn Wira, Karen Bush.   

Abstract

Escherichia coli and Klebsiella pneumoniae isolates with extended-spectrum beta-lactamases (ESBLs) or AmpC cephalosporinases generally respond as predicted to NCCLS tests for ESBL production. However, inoculum size may affect MICs. The effect of inoculum level in clinical isolates expressing beta-lactamases were studied at inocula within 0.5 log unit of the standard inoculum, using broth microdilution methodology with ceftazidime, cefotaxime, cefepime, cefpodoxime, and aztreonam. Strains with TEM-1 or no beta-lactamases gave consistent MIC results with inocula of 10(5) and 10(6) CFU/ml. When the bacteria were screened for ESBL production and the lower inoculum was used, several strains with ESBLs, including CTX-M-10, TEM-3, TEM-10, TEM-12, TEM-6, SHV-18, and K1, gave false-negative results for one or more antimicrobial agents (MICs below the NCCLS screening concentration for detecting suspected ESBLs). When the higher inoculum was used, MICs of at least one antimicrobial agent increased at least fourfold in strains producing TEM-3, TEM-10, TEM-28, TEM-43, SHV-5, SHV-18, and K1. All antimicrobial agents showed an inoculum effect with at least one ESBL producer. Confirmatory clavulanate effects were seen for both inocula for all ESBL-producing strains with all antimicrobial agents tested, except for the CTX-M-10-producing E. coli with ceftazidime and the SHV-18-producing K. pneumoniae with cefotaxime. In kinetic studies, cefpodoxime and cefepime were hydrolyzed by ESBLs in a manner similar to that of cefotaxime. When total beta-lactamase activity and hydrolysis parameters were evaluated, however, no single factor was predictive of inoculum effects. These results indicate that the NCCLS screening and confirmation tests are generally predictive of ESBL production, but false-negative results can arise when a lower inoculum is used in testing.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14715764      PMCID: PMC321709          DOI: 10.1128/JCM.42.1.269-275.2004

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  32 in total

1.  In vitro and in vivo activities of amikacin, cefepime, amikacin plus cefepime, and imipenem against an SHV-5 extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain.

Authors:  D Szabó; A Máthé; Z Filetóth; P Anderlik; L Rókusz; F Rozgonyi
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

Review 2.  New beta-lactamases in gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy.

Authors:  K Bush
Journal:  Clin Infect Dis       Date:  2001-03-21       Impact factor: 9.079

3.  Effect of inoculum size on the antibacterial activity of cefpirome and cefepime against Klebsiella pneumoniae strains producing SHV extended-spectrum beta-lactamases.

Authors:  B Bedenić; N Beader; Z Zagar
Journal:  Clin Microbiol Infect       Date:  2001-11       Impact factor: 8.067

Review 4.  Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat.

Authors:  P A Bradford
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

5.  Cloning and biochemical characterization of FOX-5, an AmpC-type plasmid-encoded beta-lactamase from a New York City Klebsiella pneumoniae clinical isolate.

Authors:  A M Queenan; S Jenkins; K Bush
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

6.  Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime.

Authors:  Annie Wong-Beringer; Janet Hindler; Michael Loeloff; Anne Marie Queenan; Nancy Lee; David A Pegues; John P Quinn; Karen Bush
Journal:  Clin Infect Dis       Date:  2001-12-04       Impact factor: 9.079

Review 7.  Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory.

Authors:  D L Paterson; W C Ko; A Von Gottberg; J M Casellas; L Mulazimoglu; K P Klugman; R A Bonomo; L B Rice; J G McCormack; V L Yu
Journal:  J Clin Microbiol       Date:  2001-06       Impact factor: 5.948

8.  Characterization of the extended-spectrum beta-lactamase reference strain, Klebsiella pneumoniae K6 (ATCC 700603), which produces the novel enzyme SHV-18.

Authors:  J K Rasheed; G J Anderson; H Yigit; A M Queenan; A Doménech-Sánchez; J M Swenson; J W Biddle; M J Ferraro; G A Jacoby; F C Tenover
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

9.  Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae.

Authors:  K S Thomson; E S Moland
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

10.  In vitro activities of various beta-lactam antimicrobial agents against clinical isolates of Escherichia coli and Klebsiella spp. resistant to oxyimino cephalosporins.

Authors:  B D Jett; D J Ritchie; R Reichley; T C Bailey; D F Sahm
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191

View more
  41 in total

1.  Emergence of community-acquired extended-spectrum beta-lactamase Escherichia coli (ESBLEC) in Honolulu: a case series of three individuals with community-acquired ESBLEC bacteriuria.

Authors:  Reid R Hoshide; Heath Chung; Jinichi Tokeshi
Journal:  Hawaii Med J       Date:  2011-09

2.  Functional relationship between bacterial cell density and the efficacy of antibiotics.

Authors:  Klas I Udekwu; Nicholas Parrish; Peter Ankomah; Fernando Baquero; Bruce R Levin
Journal:  J Antimicrob Chemother       Date:  2009-02-13       Impact factor: 5.790

Review 3.  Updated functional classification of beta-lactamases.

Authors:  Karen Bush; George A Jacoby
Journal:  Antimicrob Agents Chemother       Date:  2009-12-07       Impact factor: 5.191

4.  Inoculum effect of β-lactam antibiotics.

Authors:  Justin R Lenhard; Zackery P Bulman
Journal:  J Antimicrob Chemother       Date:  2019-10-01       Impact factor: 5.790

Review 5.  Early detection of pneumonia as a risk factor for mortality in burn patients in Menoufiya University Hospitals, Egypt.

Authors:  M Mgahed; R El-Helbawy; A Omar; H El-Meselhy; R Abd El-Halim
Journal:  Ann Burns Fire Disasters       Date:  2013-09-30

6.  The Poisoned Well: Enhancing the Predictive Value of Antimicrobial Susceptibility Testing in the Era of Multidrug Resistance.

Authors:  Thea Brennan-Krohn; Kenneth P Smith; James E Kirby
Journal:  J Clin Microbiol       Date:  2017-05-03       Impact factor: 5.948

7.  Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method.

Authors:  Thea Brennan-Krohn; James E Kirby
Journal:  J Vis Exp       Date:  2019-04-18       Impact factor: 1.355

8.  Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase.

Authors:  Krisztina M Papp-Wallace; Christopher R Bethel; Anne M Distler; Courtney Kasuboski; Magdalena Taracila; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2009-12-14       Impact factor: 5.191

Review 9.  Cefepime: a reappraisal in an era of increasing antimicrobial resistance.

Authors:  Andrea Endimiani; Federico Perez; Robert A Bonomo
Journal:  Expert Rev Anti Infect Ther       Date:  2008-12       Impact factor: 5.091

10.  Compensation of the metabolic costs of antibiotic resistance by physiological adaptation in Escherichia coli.

Authors:  Nadine Händel; J Merijn Schuurmans; Stanley Brul; Benno H ter Kuile
Journal:  Antimicrob Agents Chemother       Date:  2013-05-28       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.